Evidence map›Paper›PMID 29950580›Full record

ReviewNPJ schizophrenia2018

The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data.

Marsha A Wilcox, Adam J Savitz, Anjené M Addington, Gary S Gray, Eva C Guinan, John W Jackson, Thomas Lehner, Sharon-Lise Normand, Hardeep Ranu, Geetha Senthil and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ schizophrenia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Marsha A WilcoxJanssen Pharmaceutical Research and Development, Titusville, NJ, USA. MWilcox@its.jnj.com.
Adam J SavitzJanssen Pharmaceutical Research and Development, Titusville, NJ, USA.
Anjené M AddingtonGenomics Research Branch, National Institute of Mental Health in Bethesda, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-7770-299X
Gary S GrayHarvard Catalyst|The Harvard Clinical and Translational Science Center, Harvard Medical School, Boston, MA, USA.
Eva C GuinanDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
John W JacksonDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Thomas LehnerOffice of Genomics Research Coordination, National Institute of Mental Health, Bethesda, USA.
Sharon-Lise NormandDepartment of Health Care Policy (Biostatistics), Harvard Medical School, Boston, MA, USA.
Hardeep RanuHarvard Catalyst|The Harvard Clinical and Translational Science Center, Harvard Medical School, Boston, MA, USA.
Geetha SenthilOffice of Genomics Research Coordination, National Institute of Mental Health, Bethesda, USA.
Jake SpertusDepartment of Health Care Policy (Biostatistics), Harvard Medical School, Boston, MA, USA.
Linda ValeriDepartment of Psychiatry, Harvard Medical School, Boston, MA, USA.
Joseph S RossSection of General Internal Medicine and the National Clinician Scholars Program, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
Harvard University · USNational Institute of Mental Health · USJanssen (United States) · USYale New Haven Hospital · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
NCATS NIH HHS UL1 TR001102NIMH NIH HHS L30 MH111012
6 · The paper itself

Abstract

Clinical trial data are the gold standard for evaluating pharmaceutical safety and efficacy. There is an ethical and scientific imperative for transparency and data sharing to confirm published results and generate new knowledge. The Open Translational Science in Schizophrenia (OPTICS) Project was an open-science initiative aggregating Janssen clinical trial and NIH/NIMH data from real-world studies and trials in schizophrenia. The project aims were to show the value of using shared data to examine: therapeutic safety and efficacy; disease etiologies and course; and methods development. The success of project investigators was due to collaboration from project applications through analyses, with support from the Harvard Catalyst. Project work was independent of Janssen; all intellectual property was dedicated to the public. Efforts such as this are necessary to gain deeper insights into the biology of disease, foster collaboration, and to achieve the goal of developing better treatments, reducing the overall public health burden of devastating brain diseases.

Identifiers

PMID29950580
PMCPMC6021398
OpenAlexW2809681969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.